Hepatitis C Virus Infection and Diabetic Microvascular Complications  by Abdel Aziz, Mohamed Y. et al.
13 
 
 
 
Hepatitis C Virus Infection and Diabetic Microvascular 
Complications 
 
Mohamed Y. Abdel Aziz* MD,  Mahmoud M El-Bendary#,   
Mohamed M El-Arman@ 
Departments of Internal Medicine *, Tropical Medicine# and 
Clinical Pathology@, Mansoura Univesity, Mansoura, Egypt 
 
 
 
 
 
 
Abstract 
The microvascular complications are the important cause of mortality and morbidity of 
either type 1 or 2 DM. Great efforts have been made to recognize the possible 
susceptibility or etiologic factors of these complications; whether genetic or 
environmental. Hepatitis C virus infection is another prevalent problem in our 
community. 
The present work aimed to study the possible impact, if any of HCV infection on 
microvascular complications. A total 70 diabetic patients 17 type 1 and 53 type 2, were 
included (20 males and 50 females) with age ranging from 13 to 72 years and 30 healthy 
volunteers with matched age and sex were taken as a control group. 
Complete history taking and full clinical examination were done. Laboratory work up was 
done for patients and control including urinalysis, blood sugar, serum creatinine, urinary 
albumin excretion, lipogram, liver function tests, HbAlc and HCV antibodies. Fundus 
examination was done for patients and control.  
Diabetics were found to have a prevalence rate of HCV infection of 32%. Prevalence of 
microvascular complication, nephropathy, retinopathy & neuropathy were found to be 
relatively higher in diabetics with HCV infection. 
Advanced grades of microvascular complication were more prevalent in HCV-positive 
diabetics. It was concluded that HCV infection is possibly a potential aggravating factor 
for microvascualr complications. 
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Introduction 
 
he prevalence of diabetes and its 
complications is increasing 
nowadays. Vascular complications of 
DM are a common cause of mortality 
and morbidity in diabetics. These 
complications constitute the major 
clinical burden in diabetes but their 
pathogenesis is poorly understood1.  
Type 1 and 2 diabetes have the distinct 
etiologies, but patients with either 
disease are at risk of developing the 
same range of microvascular and 
macrovascular complications including 
nephropathy, neuropathy, retinopathy 
and atherosclerosis.  
Throughout the world, the number of 
patients requiring hemodialysis for 
diabetic nephropathy has increased 
enormously2. Although several factors, 
such as poor glucose control3, increased 
BP4, proteinuria5, lipid abnormalities6, 
and genetic problems7, can be identified 
contributing to the progression of 
diabetic nephropathy, it is highly 
suspected that there may be other 
prognostic factors for the deterioration 
of this disease.  
Hyperglycemia advanced glycosylation 
end products (AGES), growth factors 
and cytokines together with other 
factors have been identified as 
participants in the pathogenesis of these 
complications3. 
Type 2 diabetes is more common in 
those with than in those without HCV 
infection8. Thus HCV promote the 
development of type 2 diabetes in 
susceptible individuals. Hepatic 
steatosis and cirrhosis, both features of 
HCV infection, have been associated 
with abnormal glucose regulation9 and 
insulin resistance10.  Interestingly, a high 
prevalence of HCV infection was 
recently reported in diabetic patients11.   
Mixed cryoglobulinemia, renal 
syndromes, lymphoproliferative 
disorders, Sjogren syndrome, porphyria 
cutanea tarda, and neuropathies are all 
strongly associated with hepatitis C 
virus (HCV) infection. Diabetes, thyroid 
disease, and the presence of 
autoantibodies in the serum are also 
linked to HCV, but less strongly. The 
pathophysiologic basis for most of these 
syndromes seems immunologic 12. 
The prevalence of HCV infection was 
investigated in the biopsied patients. 
The highest prevalence of HCV infection 
was found in type 2 diabetic-related 
glomerulosclerosis (II-DGS)13. The 
patient's positive for HCV antibody 
with diabetic glomerulosclerosis may 
rapidly progress to end-stage renal 
failure and need hemodialysis. The 
decline of renal function reflected by the 
slope of reciprocal serum creatinine was 
significantly greater in the HCV-positive 
group than in the HCV-negative 
group14.   
The present work aimed to study the 
impact of HCV infection, if any on the 
diabetic microvascular complications 
regarding nephropathy, retinopathy and 
neuropathy.  
Material and Methods 
Patients of the present work were 
recruited from that regularly attending 
outpatient clinic of diabetes and 
endocrine unit, Mansoura Specialized 
Medical University Hospital. A total of 
70 diabetic patients (17 type 1 and 53 
type 2) were included, 20 male and 50 
females, with age ranging from 13 to 73 
years. Thirty normal healthy volunteers, 
of matched age and sex were taken as a 
control group. Patients were subjected 
to complete history taking and thorough 
clinical examination with stress on 
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manifestations of peripheral 
neuropathy, autonomic neuropathy, BP 
and cardiovascular status.  
Investigations done included complete 
urinalysis, urinary albumin excretion, 
serum creatinine and creatinine 
clearance, lipogram. Liver function tests 
included SGOT, SGPT, HbAlc, HCV-
antibodies and fundus examination. 
All patients have been Hepatitis B 
antigen negative. The diagnosis of 
nephropathy was considered by the 
presence of persistent albuminuria of 20 
to 200 mg/24 hours (microalbuminuria) 
on at least three occasions in absence of 
UTI. Macroalbuminuria was diagnosed 
when persistent albuminuria equals or 
exceeds 300 mg/24 hours15. 
Assay of HCV antibodies screened by 
3rd generation ELIZA of Abbot 
Diagnostics, North Chicago, USA and 
HBsAg by latex slide test kit provided 
by Omega Diagnostic Limited, England. 
Radioimmunoassay typing for 
microalbuminuria: Method described by 
Mangili and his co-workers 16 was used. 
Urinary concentration was measured by 
Radioimmunoassay, where urine 
samples were stored at -20o c. Urine 
specimen were thawed only once before 
measurement. The inter- and intra-assay 
coefficients of variation for UAE were 11 
and 4% respectively. 
Statistical analysis: X2 test with Yates 
correction or Fisher, S exact test tested 
difference in prevalence when 
appropriate. Student t-test or Wilcoxan 
S test analyzed continuous variables 
expressed as mean and standard 
deviation when appropriate.  The 
statistical analysis of the present work 
was done by IBM personal computer 
using EXCEL statistical program, 
accepted level of significance for P value 
0.05. 
 
Results 
 t-test was applied for numbers and chi-
square for percentages (Tables 1-7). 
Discussion 
Both hepatitis C virus infection and 
diabetes are common health problems in 
our country. Hepatitis C virus is known 
to have a wide variety of manifestations 
in the kidney. The renal manifestations 
of HCV include direct effects in the 
kidney, such as membranous 
nephropathy, cryoglobulinemia, and 
membranoproliferative type of the 
glomerulonephritis. The presence of 
HCV worsens the progression of several 
renal diseases, and, like chronic renal 
disease, HCV is more prevalent in 
patients with type 2 diabetic 
nephropathy. Therefore, it is possible 
that HCV contributes to the excess of 
renal disease 10, 14. 
In the  present study, prevalence rate of 
HCV infection among diabetics was 
found to be 25 out of 70 (35.7%) and it is 
significantly higher (10%) than normal 
control (Table 1). Type 2 diabetes is 
more common in those with than in 
those without HCV infection. Thus HCV 
promote the development of type 2 
diabetes in susceptible individuals 17,8. 
Hepatic steatosis and cirrhosis, both 
features of HCV infection, have been 
associated with glucose regulation and 
insulin resistance 18.  
It was also found that diabetics having 
HCV infection are more at risk to 
develop macroalbuminuria (Table 4) 
and proliferative retinopathy (Table 6) 
than those without HCV infection are. 
Moreover, the overall prevalence of 
proteinuria and retinopathy was higher 
in HCV-positive compared to HCV-
negative diabetics (Table 2). 
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Table 1: Comparative analysis of the patients and  controls (clinical and biochemical 
characteristics) 
Characteristics Patients (n=70) Controls  (n= 30) 
 Age (years) 47 r 18 45 r 13 
 BMI 26.8±2.3 26±3 
  
 Gender [M/F] 20 / 50 9 / 21 
DM type [1] (n/%) 
                [2]  
17 / 24.3% 
53 / 75.7% 
- 
   
Neuropathy (n/%) 
       Peripheral 
       Autonomic  
40 / 57.2% 
40 / 57.2% 
11 / 15.7% 
- 
 Nephropathy (n/%) 29 / 41.4% - 
 Retinopathy (n/%) 20 / 28.6% - 
 Hypertension  (n/%) 22 / 31.4% - 
 MAP (mmHg) 100 r 15* 88 r 6 
 HCV infection (n/%) 25 / 35.7%* 3 / 10% 
 HBV infection (n/%) 0 / 0% 0 / 0% 
 Serum Creatinine (mg%) 0.95 r 0.1* 0.82 r 0.1 
 Serum Triglycerides (mg%) 119 r 36* 100 r 30 
 Serum Cholesterol (mg%) 195 r 35* 168 r 31 
 HbA1c (gm%) 8.2 r 2.5* 5.2 r 0.6 
 Creatinine clearance (ml/min) 126 r 31* 102 r 13 
 UAE  (ug/ml) 64 r 59* 11 r 5 
* Significant difference between the two groups (P d 0.05). 
The data expressed in absolute number and percentage or mean and standard deviation.  
Abbreviations: n, number; BMI, body mass index; DM, diabetes mellitus; M, male; F, female; MAP, 
mean arterial pressure; HA1c, glcosylated hemoglobin;  HCV, hepatitis C virus; HBV, hepatitis B virus;  
UAE, urinary albumin excretion. 
The degree of proteinuria was 
significantly greater in HCV-positive 
diabetic patients (111 r 79) than in HCV-
negative diabetic patients (43 r 35). 
Serum creatinine levels and mean 
arterial pressure tended to be higher in 
HCV-positive diabetic patients (0.97 r 
0.12 mg%, 104 r 6) than in HCV-
negative diabetic patients (0.81 r 
0.11mg%, 93 r 15) respectively (Table 
2). These results and the association of 
the degree of proteinuria with the 
deterioration of renal function 
emphasize that HCV infection may 
influence the progression of diabetic 
nephropathy.  
Unlike our study, the Japanese study 
did not show a significant difference in 
progression to ESRD between HCV and 
non-HCV diabetic patients11. However, 
similar to our findings, the rate of 
progression of renal disease was worse 
in the HCV group19.   
We can only speculate as to why 
diabetic patients with HCV have worse 
renal survival. However, we have 
observed in a separate work that an 
elevated anti-nuclear antibody predicts 
worsens renal survival in a cohort of 
diabetic and nondiabetic HCV patients. 
Whether this serologic test indicates 
increased autoimmunity, which is 
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sometimes seen with HCV, or is a 
marker for increased inflammation or 
both is not clear at this time. Poorer 
renal survival in the HCV group may be 
due to direct effects of HCV in the 
kidney. It was due to HCV-related 
glomerular disease19. 
Ferri and his co-workers20 reported that 
circulating cryoglobulins and immune 
complexes could be deposited into small 
and medium sized vasculature. These 
cryoglobulins and immune complexes 
are found in cases with chronic HCV 
infection21. Moreover, Garcoa-
Valdecases and his co-workers23 
reported that HCV infection is 
associated with membranoproliferative 
glomerulonephritis and nephrotic 
syndrome. Okada et al24 found immune 
complex deposition, cryoglobulin-like 
structure, and HCV core protein in the 
glomeruli of those affected patients25.  
We have some interesting theories. 
Immune complex glomerulonephritis 
has been reported to occur at a higher 
frequency in patients with diabetic 
nephropathy than in the nondiabetic 
population(23). We must bear in mind 
that associated immune mediated 
glomerulonephritis in patients with 
diabetic nephropathy usually displays a 
rapid progression to renal failure25.  
Table 2: Comparative analysis of the patients with and without HCV positive antibodies 
Characteristics HCV negative group (n=45) HCV  positive 
group (n=25) 
Diabetic nephropathy (n/%) 
     Microalbuminuria 
     Macroalbuminuria 
15 / 33.3% 
10 / 22.2% 
5 / 11.1% 
14 / 56%* 
8 / 32% 
6 / 24%* 
Diabetic retinopathy (n/%) 
     Non-proliferative 
     Proliferative 
11 / 24.4% 
6 / 13.3% 
5 / 11.1% 
9 / 36% 
4 / 16% 
5 / 20% 
Neuropathy (n/%) 
       Peripheral 
       Autonomic 
21 / 46.7% 
21 / 46.7% 
5 / 11.1% 
19 / 76%* 
19 / 76% 
6 / 24%* 
Diabetic duration (months) 94 r 55 101 r 78 
DM type [1] (n/%) 
                [2] 
12  / 27% 
33 / 73% 
5 / 20% 
20 / 80% 
Hypertension (n/%) 13 / 28.9% 9 / 36% 
MAP (mmHg) 93 r 15 104 r 6* 
Serum Creatinine (mg%) 0.81 r 0.11 0.97 r 0.12* 
Serum Triglycerides (mg%) 109 r 33 123 r 36* 
Serum Cholesterol (mg%) 166 r 32 195 r 36* 
HbA1c (gm%) 7.9 r 2.2 8.3 r 2.3 
Creatinine Clearance (ml/min) 111 r 21 121 r 23 
UAE (ug/ml) 43 r 35 111 r 79* 
*Significant difference between the two groups (P d 0.05).  
The data expressed in absolute number and percentage or mean and standard deviation.  
Abbreviations: n, number; DM, diabetes mellitus; MAP, mean arterial pressure; HbA1c, glcosylated 
hemoglobin;  HCV, hepatitis C virus;  UAE, urinary albumin excretion. 
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Table 3: Comparative analysis of the patients with and without nephropathy in HCV diabetics 
Characteristics Nephropathy group (14) Non-Nephropathy 
group (11) 
Diabetic duration (months) 109 r 68  103 r 45 
MAP (mmHg) 108 r 12* 97 r 15 
Retinopathy (n/%) 6 / 42.8% 3 / 27.3% 
Autonomic neuropathy (n/%) 4 / 28.6% 2 / 18.2% 
Serum Triglycerides (mg%) 119 r 37 117 r 33 
Serum Cholesterol (mg%) 191 r 43 171 r 36 
HbA1c (gm%) 8.4 r 2.8 8.5 r 1.6 
Serum Creatinine (mg%) 0.98 r 0.12* 0.86 r 0.11 
Creatinine Clearance (ml/min) 129 r 28* 104 r 17 
UAE  (ug/ml) 138 r 30* 18 r 14 
* Significant difference between the two groups (P d 0.05). 
The data expressed in absolute number and percentage or mean and standard deviation.  
 
Table 4:  Comparative analysis between the macroalbuminuric, microalbuminuric and 
normoalbuminuric diabetic groups 
Characteristics MAA (n: 11) MIA (n: 18) NA (n: 41) 
Diabetic duration (months) 109 r 88a 102 r 67a 89 r 46 
MAP (mmHg) 110 r  15a 101 r 15 97 r 14 
Retinopathy (n/%) 5 / 45%a 7 / 38.9%a 8 / 19.5% 
HbA1c (gm%) 9.2 r 2.4a 8.8 r 3a 7.4 r 1.8 
Creatinine Clearance (ml/min) 111 r 10ab 135 r 29a 121 r 16 
HCV (n/%) 7 / 63.6% a 10 / 55.5% a 8 / 19.5% 
* a significant difference between the two groups (P d 0.05). 
The data expressed in absolute number and percentage or mean and standard deviation.  
Abbreviations: macroalbuminuria (MAA), microalbuminuria (MIA) and normoalbuminuria (NA); n, 
number; MAP, mean arterial pressure; HA1c, glcosylated hemoglobin;  HCV, hepatitis C virus;   
a = P d 0.05 compared to NA;  b = P d 0.05 MAA compared to MIA groups. 
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Table 5: Comparative analysis of the patients with and without retinopathy in HCV diabetics 
Characteristics Retinopathy group (9) Non 
Retinopathy 
group (16) 
Diabetic duration (months) 107 r 66 100 r 43 
MAP (mmHg) 109 r 17* 95 r 14 
Nephropathy (n/%) 6 / 67%* 8 / 50% 
Autonomic Neuropathy (n/%) 3 / 33.3%* 3 / 18.8% 
HbA1c (gm%) 8.8 r 2.6 8.1 r 2.6a 
UAE  (ug/ml) 148 r 33* 28 r 14 
*Significant difference between the two groups (P d 0.05).  
The data expressed in absolute number and percentage or mean and standard deviation.  
Table 6: Comparative analysis of the proliferative retinopathy   (PDR) background- 
retinopathy (BGDR), and non-retinopathy diabetic (NDR) groups 
Characteristics PDR  (10) BDR (10) NDR (50) 
Diabetic duration (months) 110 r 72* 99 r 86* 86 r 64 
MAP (mmHg) 107 r 16 100 r 13 100 r 15 
Nephropathy (n/%) 6 / 60% a 6 / 50% 17 / 36% 
HbA1c (gm%) 9.1 r 2a 8.2 r 3 7.9 r 2.2 
UAE  (ug/ml) 147 r 98ab 40 r 37 50 r 73 
HCV (n/%) 6 / 60% a 5 / 50% 14 / 28% 
*Significant difference between the two groups (P d 0.05) 
The data expressed in Absolute   number and percentage or mean and standard deviation. 
Abbreviations: proliferative retinopathy (PDR), background retinopathy (BDR) and no retinopathy 
(NDR) n, number; MAP, mean arterial pressure; HA1c, glcosylated hemoglobin;  HCV, hepatitis C virus;  
a = P d 0.05 compared to NDR;  b = P d 0.05 PDR compared to BDR groups. 
Table 7: Comparative analysis of the neuropathy, non-neuropathy in HCV diabetic patients 
Characteristics Neuropathy 
(19) 
Non neuropathy 
(6) 
Diabetic duration (months) 107 r 66 101 r 43 
MAP (mmHg) 97 r 13* 106 r 16 
Retinopathy (n/%) 7 / 36.8% 2 / 33.3% 
Nephropathy  (n/%) 11 / 57.9% 3 / 50% 
HbA1c (gm%) 8.8 r 2.6 8.1 r 2.6 
UAE  (ug/ml) 118 r 33* 28 r 14 
 * Significant difference between the two groups (P d 0.05). 
The data expressed in absolute number and percentage or mean and standard deviation.  
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It is well known that HCV infection 
causes frequently cirrhosis. In cirrhosis, 
an intense intrarenal vasoconstriction 
and hypoperfusion contribute to the 
rapid deterioration of renal function23.  
As a possible mechanism to link HCV to 
diabetes, it has been postulated that 
HCV could infect pancreatic islet cells 
and thereby directly induce damage to 
cell8. Therefore, the possibility that HCV 
may infect renal tissue, such mesangial 
cells, and contribute to renal damage 
directly cannot be excluded26. 
In present work, from 14 cases with 
diabetic nephropathy and HCV 
infection only 6 have retinopathy (Table 
3). Other non-diabetic causes should be 
scrutinized but, in absence of renal 
biopsy it seems difficult to suggest HCV 
infection to be behind, at least, some of 
these cases. Obviously, further studies 
are needed to clarify this issue.  
Diabetic retinopathy is known to be 
present in virtually all diabetics with 
nephropathy, and absence of 
retinopathy should lead to more than 
usual consideration of other non-
diabetic causes of renal disease27.  
Renal biopsies were done in patients 
with diabetes because the history was 
inconsistent with diabetic nephropathy 
(hematuria, heavy proteinuria in 
absence of retinopathy, or short history 
of diabetes). Likewise, it found that 
diabetic patients with HCV were less 
likely to have diabetic nephropathy as 
their primary diagnosis.  
On the other hand, 3 out of 9 cases with 
retinopathy and HCV infection did not 
have proteinuria (Table 5). West and his 
co-workers29 confirmed that up to one 
third of cases with diabetic retinopathy, 
even of the proliferative type, may occur 
in absence of renal disease or 
proteinuria. Physicians who confirm the  
presence    of    HCV   in   patients    with  
 
diabetes, should be aware of their 
increased risk for advanced diabetic 
nephropathy and should pay close 
attention to other modifiable risk 
factors, such as blood pressure control. It 
is important that prospective studies be 
performed to confirm these preliminary 
observations.  
In conclusion, we must pay attention to 
HCV infection in diabetic patients, since 
a high prevalence of HCV infection is 
observed and it may have an adverse 
effect on the progression of diabetic 
nephropathy. However, the accurate 
reason for the rapid progression of HCV 
induced glomerulosclerosis remains 
uncertain.  In other words, HCV 
infection in diabetics could be 
considered as a potential aggravating 
factor for the microangiopathic 
complications. Frequent check ups and 
close monitoring has to be done for 
diabetics with HCV infection with 
special consideration to renal and retinal 
complications. 
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